Ex-Blackstone India co-head Mathew Cyriac’s fund buys 80% stake in Accutest Research Laboratories

In the next five years, drug patents with sales worth $170 billion will expire globally, driving demand for cost-effective generic drugs. Among the drugs losing patent, the share for specialty medicines like Biologics, inhalers, injectables, and transdermal is 54%, and the remaining 46% is oral. As a result, Accutest services are increasingly focused on specialty medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IgtqYJ5
via IFTTT